Myeloid-Derived Suppressor Cells in Hematologic Diseases: Promising Biomarkers and Treatment Targets
2019
Аутори
Bizymi, NikoletaBjelica, Sunčica
Kittang, Astrid Olsnes
Mojsilović, Slavko
Velegraki, Maria
Pontikoglou, Charalampos
Roussel, Mikael
Ersvaer, Elisabeth
Santibanez, Juan F.
Lipoldova, Marie
Papadaki, Helen A.
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
Myeloid-derived suppressor cells (MDSC) are a heterogeneous group of immature myeloid cells that exist at very low numbers in healthy subjects but can expand significantly in malignant, infectious, and chronic inflammatory diseases. These cells are characterized as early-MDSCs, monocytic-MDSCs, and polymorphonuclear-MDSCs and can be studied on the basis of their immunophenotypic characteristics and their functional properties to suppress T-cell activation and proliferation. MDSCs have emerged as important contributors to tumor expansion and chronic inflammation progression by inducing immunosuppressive mechanisms, angiogenesis and drug resistance. Most experimental and clinical studies concerning MDSCs have been mainly focused on solid tumors. In recent years, however, the implication of MDSCs in the immune dysregulation associated with hematologic malignancies, immune-mediated cytopenias and allogeneic hemopoietic stem cell transplantation has been documented and the potential role of... these cells as biomarkers and therapeutic targets has started to attract a particular interest in hematology. The elucidation of the molecular and signaling pathways associated with the generation, expansion and function of MDSCs in malignant and immune-mediated hematologic diseases and the clarification of mechanisms related to the circulation and the crosstalk of MDSCs with malignant cells and other components of the immune system are anticipated to lead to novel therapeutic strategies. This review summarizes all available evidence on the implication of MDSCs in hematologic diseases highlighting the challenges and perspectives arising from this novel field of research.
Извор:
Hemasphere, 2019, 3, 1Издавач:
- Lippincott Williams & Wilkins, Philadelphia
Финансирање / пројекти:
- COST action
- COST action [BM1404 - Mye-EUNITER]
- Alexander S. Onassis, Public Benefit Foundation in Greece Scholarship
DOI: 10.1097/HS9.0000000000000168
ISSN: 2572-9241
PubMed: 31723807
WoS: 000507915600007
Scopus: 2-s2.0-85087829414
Институција/група
Institut za medicinska istraživanjaTY - JOUR AU - Bizymi, Nikoleta AU - Bjelica, Sunčica AU - Kittang, Astrid Olsnes AU - Mojsilović, Slavko AU - Velegraki, Maria AU - Pontikoglou, Charalampos AU - Roussel, Mikael AU - Ersvaer, Elisabeth AU - Santibanez, Juan F. AU - Lipoldova, Marie AU - Papadaki, Helen A. PY - 2019 UR - http://rimi.imi.bg.ac.rs/handle/123456789/962 AB - Myeloid-derived suppressor cells (MDSC) are a heterogeneous group of immature myeloid cells that exist at very low numbers in healthy subjects but can expand significantly in malignant, infectious, and chronic inflammatory diseases. These cells are characterized as early-MDSCs, monocytic-MDSCs, and polymorphonuclear-MDSCs and can be studied on the basis of their immunophenotypic characteristics and their functional properties to suppress T-cell activation and proliferation. MDSCs have emerged as important contributors to tumor expansion and chronic inflammation progression by inducing immunosuppressive mechanisms, angiogenesis and drug resistance. Most experimental and clinical studies concerning MDSCs have been mainly focused on solid tumors. In recent years, however, the implication of MDSCs in the immune dysregulation associated with hematologic malignancies, immune-mediated cytopenias and allogeneic hemopoietic stem cell transplantation has been documented and the potential role of these cells as biomarkers and therapeutic targets has started to attract a particular interest in hematology. The elucidation of the molecular and signaling pathways associated with the generation, expansion and function of MDSCs in malignant and immune-mediated hematologic diseases and the clarification of mechanisms related to the circulation and the crosstalk of MDSCs with malignant cells and other components of the immune system are anticipated to lead to novel therapeutic strategies. This review summarizes all available evidence on the implication of MDSCs in hematologic diseases highlighting the challenges and perspectives arising from this novel field of research. PB - Lippincott Williams & Wilkins, Philadelphia T2 - Hemasphere T1 - Myeloid-Derived Suppressor Cells in Hematologic Diseases: Promising Biomarkers and Treatment Targets IS - 1 VL - 3 DO - 10.1097/HS9.0000000000000168 ER -
@article{ author = "Bizymi, Nikoleta and Bjelica, Sunčica and Kittang, Astrid Olsnes and Mojsilović, Slavko and Velegraki, Maria and Pontikoglou, Charalampos and Roussel, Mikael and Ersvaer, Elisabeth and Santibanez, Juan F. and Lipoldova, Marie and Papadaki, Helen A.", year = "2019", abstract = "Myeloid-derived suppressor cells (MDSC) are a heterogeneous group of immature myeloid cells that exist at very low numbers in healthy subjects but can expand significantly in malignant, infectious, and chronic inflammatory diseases. These cells are characterized as early-MDSCs, monocytic-MDSCs, and polymorphonuclear-MDSCs and can be studied on the basis of their immunophenotypic characteristics and their functional properties to suppress T-cell activation and proliferation. MDSCs have emerged as important contributors to tumor expansion and chronic inflammation progression by inducing immunosuppressive mechanisms, angiogenesis and drug resistance. Most experimental and clinical studies concerning MDSCs have been mainly focused on solid tumors. In recent years, however, the implication of MDSCs in the immune dysregulation associated with hematologic malignancies, immune-mediated cytopenias and allogeneic hemopoietic stem cell transplantation has been documented and the potential role of these cells as biomarkers and therapeutic targets has started to attract a particular interest in hematology. The elucidation of the molecular and signaling pathways associated with the generation, expansion and function of MDSCs in malignant and immune-mediated hematologic diseases and the clarification of mechanisms related to the circulation and the crosstalk of MDSCs with malignant cells and other components of the immune system are anticipated to lead to novel therapeutic strategies. This review summarizes all available evidence on the implication of MDSCs in hematologic diseases highlighting the challenges and perspectives arising from this novel field of research.", publisher = "Lippincott Williams & Wilkins, Philadelphia", journal = "Hemasphere", title = "Myeloid-Derived Suppressor Cells in Hematologic Diseases: Promising Biomarkers and Treatment Targets", number = "1", volume = "3", doi = "10.1097/HS9.0000000000000168" }
Bizymi, N., Bjelica, S., Kittang, A. O., Mojsilović, S., Velegraki, M., Pontikoglou, C., Roussel, M., Ersvaer, E., Santibanez, J. F., Lipoldova, M.,& Papadaki, H. A.. (2019). Myeloid-Derived Suppressor Cells in Hematologic Diseases: Promising Biomarkers and Treatment Targets. in Hemasphere Lippincott Williams & Wilkins, Philadelphia., 3(1). https://doi.org/10.1097/HS9.0000000000000168
Bizymi N, Bjelica S, Kittang AO, Mojsilović S, Velegraki M, Pontikoglou C, Roussel M, Ersvaer E, Santibanez JF, Lipoldova M, Papadaki HA. Myeloid-Derived Suppressor Cells in Hematologic Diseases: Promising Biomarkers and Treatment Targets. in Hemasphere. 2019;3(1). doi:10.1097/HS9.0000000000000168 .
Bizymi, Nikoleta, Bjelica, Sunčica, Kittang, Astrid Olsnes, Mojsilović, Slavko, Velegraki, Maria, Pontikoglou, Charalampos, Roussel, Mikael, Ersvaer, Elisabeth, Santibanez, Juan F., Lipoldova, Marie, Papadaki, Helen A., "Myeloid-Derived Suppressor Cells in Hematologic Diseases: Promising Biomarkers and Treatment Targets" in Hemasphere, 3, no. 1 (2019), https://doi.org/10.1097/HS9.0000000000000168 . .